Article
Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma.
Current research in translational medicine - 1 Sept 2018
Arfaoui Toumi A, Blel A, Aloui R, Zaibi H, Ksentinini M, Boudaya M S, Znaidi N, Zidi Y, Aouina H, Rammeh Rommani S
Abstract excerpt
BACKGROUND: Despite recent advances, non-small cell lung cancer carries a grim prognosis. For appropriate treatment selection, the updated guidelines recommend broad molecular profiling for all patients with pulmonary adenocarcinoma. Precise histological subtyping and targeted epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing are mandatory. METHODS: Herein, we assessed the EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
